INNOVIVA, INC. Proceeds from Sale of Available-for-sale Securities
INNOVIVA, INC. (INVA) reported Proceeds from Sale of Available-for-sale Securities of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-23.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities · last filed 2018-02-23
- INNOVIVA, INC. proceeds from sale of available-for-sale securities for the quarter ending 2017-12-31 was $0.00.
- INNOVIVA, INC. proceeds from sale of available-for-sale securities for the quarter ending 2017-09-30 was $0.00.
- INNOVIVA, INC. proceeds from sale of available-for-sale securities for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. proceeds from sale of available-for-sale securities for the quarter ending 2016-09-30 was $0.00.
- INNOVIVA, INC. proceeds from sale of available-for-sale securities for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- INNOVIVA, INC. proceeds from sale of available-for-sale securities for fiscal 2016 was $3.00M, a 97.23% decline from fiscal 2015.
- INNOVIVA, INC. proceeds from sale of available-for-sale securities for fiscal 2015 was $108.08M, a 1398.78% increase from fiscal 2014.
- INNOVIVA, INC. proceeds from sale of available-for-sale securities for fiscal 2014 was $7.21M, a 68.09% decline from fiscal 2013.
| Period end | Proceeds from Sale of Available-for-sale Securities 3 month | Proceeds from Sale of Available-for-sale Securities 6 month | Proceeds from Sale of Available-for-sale Securities 9 month | Proceeds from Sale of Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $0.00 derived: sum of 2 quarters · filed 2018-02-23 | $0.00 10-K · filed 2018-02-23 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $0.00 10-Q · filed 2017-11-03 | ||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-08 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $0.00 derived: sum of 2 quarters · filed 2018-02-23 | $3.00M derived: sum of 3 quarters · filed 2018-02-23 | $3.00M 10-K · filed 2018-02-23 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $3.00M derived: sum of 2 quarters · filed 2017-11-03 | $3.00M 10-Q · filed 2017-11-03 | $53.97M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $3.00M 10-Q · filed 2017-08-08 | $53.97M derived: sum of 3 quarters · filed 2018-02-23 | $53.97M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-05 | $50.98M derived: sum of 2 quarters · filed 2018-02-23 | $50.98M derived: sum of 3 quarters · filed 2018-02-23 | $50.98M derived: sum of 4 quarters · filed 2018-02-23 |
| 2015-12-31 | $50.98M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $50.98M derived: sum of 2 quarters · filed 2018-02-23 | $50.98M derived: sum of 3 quarters · filed 2018-02-23 | $108.08M 10-K · filed 2018-02-23 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $0.00 derived: sum of 2 quarters · filed 2016-11-03 | $57.10M 10-Q · filed 2016-11-03 | $59.31M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $57.10M 10-Q · filed 2016-08-04 | $59.31M derived: sum of 3 quarters · filed 2017-02-28 | $59.31M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $57.10M 10-Q · filed 2016-05-05 | $59.31M derived: sum of 2 quarters · filed 2017-02-28 | $59.31M derived: sum of 3 quarters · filed 2017-02-28 | $59.31M derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $2.21M derived: sum of 2 quarters · filed 2017-02-28 | $2.21M derived: sum of 3 quarters · filed 2017-02-28 | $7.21M 10-K · filed 2017-02-28 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $0.00 derived: sum of 2 quarters · filed 2015-11-05 | $5.00M 10-Q · filed 2015-11-05 | $5.00M derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $5.00M 10-Q · filed 2015-08-06 | $5.00M derived: sum of 3 quarters · filed 2016-02-24 | $10.00M derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-03-31 | $5.00M 10-Q · filed 2015-05-08 | $5.00M derived: sum of 2 quarters · filed 2016-02-24 | $10.00M derived: sum of 3 quarters · filed 2016-02-24 | $22.60M derived: sum of 4 quarters · filed 2016-02-24 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $5.00M derived: sum of 2 quarters · filed 2016-02-24 | $17.60M derived: sum of 3 quarters · filed 2016-02-24 | $22.60M 10-K · filed 2016-02-24 |
| 2013-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $17.60M derived: sum of 2 quarters · filed 2014-11-04 | $22.60M 10-Q · filed 2014-11-04 | -$109.17M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | $12.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $17.60M 10-Q · filed 2014-08-07 | -$114.17M derived: sum of 3 quarters · filed 2015-02-27 | $58.81M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-03-31 | $5.00M 10-Q · filed 2014-05-07 | -$126.77M derived: sum of 2 quarters · filed 2015-02-27 | $46.21M derived: sum of 3 quarters · filed 2015-02-27 | |
| 2012-12-31 | -$131.77M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $41.21M derived: sum of 2 quarters · filed 2015-02-27 | $49.73M 10-K · filed 2015-02-27 | |
| 2012-09-30 | $172.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-01 | $181.50M 10-Q · filed 2013-11-01 | ||
| 2012-06-30 | $8.52M 10-Q · filed 2013-08-01 | |||
| 2011-12-31 | $8.57M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $8.57M derived: sum of 2 quarters · filed 2014-03-03 | $12.32M derived: sum of 3 quarters · filed 2014-03-03 | $17.32M 10-K · filed 2014-03-03 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-31 | $3.75M derived: sum of 2 quarters · filed 2012-10-31 | $8.75M 10-Q · filed 2012-10-31 | $10.77M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | $3.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | $8.75M 10-Q · filed 2012-08-01 | $10.77M derived: sum of 3 quarters · filed 2013-02-26 | |
| 2011-03-31 | $5.00M 10-Q · filed 2012-05-02 | $7.01M derived: sum of 2 quarters · filed 2013-02-26 | ||
| 2010-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $12.02M 10-K · filed 2013-02-26 | ||
| 2010-09-30 | $10.01M 10-Q · filed 2011-11-02 | |||
| 2009-12-31 | $5.00M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |